This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ali Khan A, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013;8:2733–2744. doi: 10.2147/IJN.S41521.Ali KhanAMudassirJMohtarNDarwisYAdvanced drug delivery to the lymphatic system: lipid-based nanoformulationsInt J Nanomedicine201382733274410.2147/IJN.S41521Open DOISearch in Google Scholar
Bhalekar MR, Pokale R, Bandivadekar M, Madgulkar A, Nagore P. Self Micro-Emulsifying Drug Delivery System for Lymphatic Uptake of Darunavir. J Drug Discov Develop Deliv. 2016;3:1–7.BhalekarMRPokaleRBandivadekarMMadgulkarANagorePSelf Micro-Emulsifying Drug Delivery System for Lymphatic Uptake of DarunavirJ Drug Discov Develop Deliv2016317Search in Google Scholar
Bunaciu AA, Udriştioiu EG, Aboul-Enein HY. X-Ray Diffraction: Instrumentation and Applications. Crit Rev Anal Chem. 2015;45:289–299. doi: 10.1080/10408347.2014.949616.BunaciuAAUdriştioiuEGAboul-EneinHYX-Ray Diffraction: Instrumentation and ApplicationsCrit Rev Anal Chem20154528929910.1080/10408347.2014.949616Open DOISearch in Google Scholar
Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev. 2007;59:379–402. doi: 10.1016/j.addr.2007.04.013.BunjesHUnruhTCharacterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scatteringAdv Drug Deliv Rev20075937940210.1016/j.addr.2007.04.013Open DOISearch in Google Scholar
Casteleyn C, Doom M, Lambrechts E, Van den Broeck W, Simoens P, Cornillie P. Locations of gut-associated lymphoid tissue in the 3-month-old chicken: a review. Avian Pathol. 2010;39:143–150. doi: 10.1080/03079451003786105.CasteleynCDoomMLambrechtsEVan den BroeckWSimoensPCornilliePLocations of gut-associated lymphoid tissue in the 3-month-old chicken: a reviewAvian Pathol20103914315010.1080/03079451003786105Open DOISearch in Google Scholar
Cavaco MC, Pereira C, Kreutzer B, et al. Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. Eur J Pharm Biopharm. 2017;110:76–84. doi: 10.1016/j.ejpb.2016.10.024.CavacoMCPereiraCKreutzerBEvading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid NanoparticlesEur J Pharm Biopharm2017110768410.1016/j.ejpb.2016.10.024Open DOISearch in Google Scholar
Chiu MH, Prenner EJ. Differential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions. J Pharm Bioallied Sci. 2011;3:39–59. doi: 10.4103/0975-7406.76463.ChiuMHPrennerEJDifferential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactionsJ Pharm Bioallied Sci20113395910.4103/0975-7406.76463Open DOISearch in Google Scholar
Daswadkar SC, Atole AV. Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis. J Drug Deliv Ther. 2020;10:25–3. doi: 10.22270/jddt.v10i5-s.4440.DaswadkarSCAtoleAVFormulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of PsychosisJ Drug Deliv Ther20201025310.22270/jddt.v10i5-s.4440Open DOISearch in Google Scholar
Dening TJ, Rao S, Thomas N, Prestidge CA. Oral nanomedicine approaches for the treatment of psychiatric illnesses. J Control Release. 2016;223:137–156. doi: 10.1016/j.jconrel.2015.12.047.DeningTJRaoSThomasNPrestidgeCAOral nanomedicine approaches for the treatment of psychiatric illnessesJ Control Release201622313715610.1016/j.jconrel.2015.12.047Open DOISearch in Google Scholar
Joseph E, Reddi S, Rinwa V, Balwani G, Saha R. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects. Eur J Pharm Sci. 2017;104:315–325. doi: 10.1016/j.ejps.2017.03.050.JosephEReddiSRinwaVBalwaniGSahaRDesign and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effectsEur J Pharm Sci201710431532510.1016/j.ejps.2017.03.050Open DOISearch in Google Scholar
Freitas MR, Rolim LA, Soares MF, Rolim-Neto PJ, Albuquerque MM, Soares-Sobrinho JL. Inclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia. Carbohydr Polym. 2012;89:1095–1100. doi: 10.1016/j.carbpol.2012.03.072.FreitasMRRolimLASoaresMFRolim-NetoPJAlbuquerqueMMSoares-SobrinhoJLInclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophreniaCarbohydr Polym2012891095110010.1016/j.carbpol.2012.03.072Open DOISearch in Google Scholar
Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci. 2005;26:394–404. doi: 10.1016/j.ejps.2005.07.011.GershkovichPHoffmanAUptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailabilityEur J Pharm Sci20052639440410.1016/j.ejps.2005.07.011Open DOISearch in Google Scholar
Gupta H, Bhandari D, Sharma A. Recent trends in oral drug delivery: a review. Recent Pat Drug Deliv Formul. 2009;3:162–173. doi: 10.2174/187221109788452267.GuptaHBhandariDSharmaARecent trends in oral drug delivery: a reviewRecent Pat Drug Deliv Formul2009316217310.2174/187221109788452267Open DOISearch in Google Scholar
Heera P. Shanmugam S. Nanoparticle Characterization and Application : An Overview. Int. J Curr Microbiol App Sci. 2015;4:379–386.HeeraP.ShanmugamS.Nanoparticle Characterization and Application : An OverviewInt. J Curr Microbiol App Sci20154379386Search in Google Scholar
Hirlekar R, Patil E, Bhairy S. Solid nanostructured lipid carriers loaded with silymarin for oral delivery: Formulation development and evaluation. Curr Trends Pharm Pharm Chem. 2021;3:56–67. doi: 10.18231/j.ctppc.2021.014.HirlekarRPatilEBhairySSolid nanostructured lipid carriers loaded with silymarin for oral delivery: Formulation development and evaluationCurr Trends Pharm Pharm Chem20213566710.18231/j.ctppc.2021.014Open DOISearch in Google Scholar
Jawahar N, Meyyanathan SN, Senthil V, Gowthamarajan K, Elango K. Studies on physico-chemical and pharmacokinetic properties of olanzapine through nanosuspension. J Pharm Sci Res. 2013;5:196–202.JawaharNMeyyanathanSNSenthilVGowthamarajanKElangoKStudies on physico-chemical and pharmacokinetic properties of olanzapine through nanosuspensionJ Pharm Sci Res20135196202Search in Google Scholar
Jenning V, Gohla S. Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int J Pharm. 2000;196:219–222. doi: 10.1016/S0378-5173(99)00426-3.JenningVGohlaSComparison of wax and glyceride solid lipid nanoparticles (SLN)Int J Pharm200019621922210.1016/S0378-5173(99)00426-3Open DOISearch in Google Scholar
Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems – an overview. Acta Pharm Sin B. 2013;3:361–372. doi: 10.1016/j.apsb.2013.10.001.KalepuSManthinaMPadavalaVOral lipid-based drug delivery systems – an overviewActa Pharm Sin B2013336137210.1016/j.apsb.2013.10.001Open DOISearch in Google Scholar
Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target. 2008;16:798–805. doi: 10.1080/10611860802475688.KaurCDNaharMJainNKLymphatic targeting of zidovudine using surface-engineered liposomesJ Drug Target20081679880510.1080/10611860802475688Open DOISearch in Google Scholar
Koteshwara KB, Reddy MS, Naha A, Nampoothiri M. Nanosuspensions: A novel drug delivery approach. Int J Res Ayurveda Pharm. 2011;2:162–165.KoteshwaraKBReddyMSNahaANampoothiriMNanosuspensions: A novel drug delivery approachInt J Res Ayurveda Pharm20112162165Search in Google Scholar
Liversidge G, Jenkins S, Liversidge EM. Injectable nanoparticulate olanzapine formulations. U.S. Patent No. US20050274887. November 16, 2005.LiversidgeGJenkinsSLiversidgeEMInjectable nanoparticulate olanzapine formulationsU.S. Patent No. US20050274887.November162005Search in Google Scholar
Maheswarappa MK, Desai PD. Design and in-vitro evaluation of mouth dissolving tablets of olanzapine. Asian J Pharm. 2011;5:107–113. doi: 10.4103/0973-8398.84551.MaheswarappaMKDesaiPDDesign and in-vitro evaluation of mouth dissolving tablets of olanzapineAsian J Pharm2011510711310.4103/0973-8398.84551Open DOISearch in Google Scholar
Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495:439–446. doi: 10.1016/j.ijpharm.2015.09.014.MakwanaVJainRPatelKNivsarkarMJoshiASolid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approachInt J Pharm201549543944610.1016/j.ijpharm.2015.09.014Open DOISearch in Google Scholar
Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24:645–692. doi: 10.1016/j.euroneuro.2014.03.008.MillanMJFoneKStecklerTHoranWPNegative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatmentEur Neuropsychopharmacol20142464569210.1016/j.euroneuro.2014.03.008Open DOISearch in Google Scholar
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177. doi: 10.1016/s0939-6411(00)00087-4.MüllerRHMäderKGohlaSSolid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the artEur J Pharm Biopharm20005016117710.1016/s0939-6411(00)00087-4Open DOISearch in Google Scholar
Natarajan J, Baskaran M, Humtsoe LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol. 2017;45:364–371. doi: 10.3109/21691401.2016.1160402.NatarajanJBaskaranMHumtsoeLCVadivelanRJustinAEnhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticlesArtif Cells Nanomed Biotechnol20174536437110.3109/21691401.2016.1160402Open DOISearch in Google Scholar
Patel S, Shah J, Bhairy S, Hirlekar R. Development of Curcumin loaded Nanostructured Lipid Carriers: Preparation, Characterization and Invitro Evaluation of Anti-cancer Activity Against A-549 Human Lung Cancer Cell Line. J Cancer Tumor Int. 2021;11:66–88. doi: 10.9734/JCTI/2021/v11i430162.PatelSShahJBhairySHirlekarRDevelopment of Curcumin loaded Nanostructured Lipid Carriers: Preparation, Characterization and Invitro Evaluation of Anti-cancer Activity Against A-549 Human Lung Cancer Cell LineJ Cancer Tumor Int202111668810.9734/JCTI/2021/v11i430162Open DOISearch in Google Scholar
Reddy RN, Shariff A. Solid lipid Nanoparticles: An advanced drug delivery system. Int J Pharm Sci Res. 2013;4:161–171. doi: 10.13040/IJPSR.0975-8232.4(1).161-71.ReddyRNShariffASolid lipid Nanoparticles: An advanced drug delivery systemInt J Pharm Sci Res2013416117110.13040/IJPSR.0975-8232.4(1).161-71Open DOISearch in Google Scholar
Sarraguça MC, Cruz AV, Soares SO, Amaral HR, Costa PC, Lopes JA. Determination of flow properties of pharmaceutical powders by near infrared spectroscopy. J Pharm Biomed Anal. 2010;52:484–492. doi: 10.1016/j.jpba.2010.01.038.SarraguçaMCCruzAVSoaresSOAmaralHRCostaPCLopesJADetermination of flow properties of pharmaceutical powders by near infrared spectroscopyJ Pharm Biomed Anal20105248449210.1016/j.jpba.2010.01.038Open DOISearch in Google Scholar
Shah J, Patel S, Bhairy S, Hirlekar R. Formulation optimization, characterization and in-vitro anti-cancer activity of curcumin loaded nanostructured lipid carriers. Int. J. Curr. Pharm. Res. 2022;14:31–43. doi: 10.22159/ijcpr.2022v14i1.44110.ShahJPatelSBhairySHirlekarRFormulation optimization, characterization and in-vitro anti-cancer activity of curcumin loaded nanostructured lipid carriersInt. J. Curr. Pharm. Res.202214314310.22159/ijcpr.2022v14i1.44110Open DOISearch in Google Scholar
Shahhet L, Al-Raghban A, Chehna MF. Improvement of the physicochemical properties of amoxicillin trihydrate powder by recrystallization at different pH values. Int J Pharm Pharm Sci. 2011;3:92–100.ShahhetLAl-RaghbanAChehnaMFImprovement of the physicochemical properties of amoxicillin trihydrate powder by recrystallization at different pH valuesInt J Pharm Pharm Sci2011392100Search in Google Scholar
Sumeet S, Natarajan J, Kunal J, Kuppusamy G, Subramania NM. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci. 2013;9:26–34. doi: 10.2174/1573413711309010007.SumeetSNatarajanJKunalJKuppusamyGSubramaniaNMOlanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailabilityCurr Nanosci20139263410.2174/1573413711309010007Open DOISearch in Google Scholar
Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, Lindsay De Vane C. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology. 2004;29:551–557. doi: 10.1038/sj.npp.1300372.WangJSTaylorRRuanYDonovanJLMarkowitzJSLindsay De VaneCOlanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animalsNeuropsychopharmacology20042955155710.1038/sj.npp.1300372Open DOISearch in Google Scholar